-
Primary Gastric Small Cell Carcinoma (Presenting as Linitis Plastica) Diagnosed Using Endoscopic Ultrasound-Guided Biopsy: A Case Report
-
Ra Ri Cha, Jin Kyu Cho, Wan Soo Kim, Jin Joo Kim, Jae Min Lee, Sang Soo Lee, Hyun Jin Kim
-
Clin Endosc 2019;52(3):278-282. Published online October 5, 2018
-
DOI: https://doi.org/10.5946/ce.2018.114
-
-
 Abstract
 PDF PubReader ePub
- Small cell carcinomas are the most aggressive, highly malignant neuroendocrine tumors; among these, gastric small cell carcinoma (GSCC) is extremely rare. Here we report a case of a patient with primary GSCC, presenting as linitis plastic, who was diagnosed using endoscopic ultrasound (EUS)-guided biopsy. With undiagnosed linitis plastica, an 80-year-old woman was referred to our institution. Abdominal computed tomography revealed irregular wall thickening extending from the gastric body to the antrum. Endoscopy suspected to have Borrmann type IV advanced gastric cancer. EUS of the stomach showed diffuse submucosal thickening of the gastric wall, mainly the antrum. EUS-guided bite-on-bite biopsy confirmed the diagnosis of GSCC. In general, GSCC is difficult to diagnose and careful examination is necessary to determine the therapeutic strategy; however, EUS is particularly helpful in the differential diagnosis of a lesion presenting as linitis plastica.
-
Citations
Citations to this article as recorded by  - An online tool for survival prediction of extrapulmonary small cell carcinoma with random forest
Xin Zhang
Frontiers in Oncology.2023;[Epub] CrossRef - Gastric linitis plastica due to signet-ring cell carcinoma with Krukenberg tumors diagnosed by endoscopic ultrasound-guided fine-needle aspiration
Takeshi Okamoto, Hidekazu Suzuki, Katsuyuki Fukuda
Clinical Journal of Gastroenterology.2021; 14(4): 994. CrossRef - A case report of advanced gastric small cell carcinoma with neoadjuvant chemotherapy followed by radical total gastrectomy
Bing Wang, Nanlin Jiao, Lianghui Shi
Asian Journal of Surgery.2020; 43(12): 1205. CrossRef
-
8,300
View
-
162
Download
-
3
Web of Science
-
3
Crossref
-
Fecal microbiota transplantation: present and future
-
Ra Ri Cha, Irene Sonu
-
Received October 8, 2024 Accepted December 15, 2024 Published online March 25, 2025
-
DOI: https://doi.org/10.5946/ce.2024.270
[Epub ahead of print]
-
-
Abstract
PDFPubReaderePub
- Fecal microbiota transplantation (FMT) involves transplanting fecal matter from healthy donors into patients with gut dysbiosis to restore microbial balance. It has been proven to be highly effective in treating recurrent Clostridioides difficile infection (CDI), and United States Food and Drug Administration-approved microbiome-based therapies, such as REBYOTA (fecal microbiota live-jslm) and VOWST (fecal microbiota spores live-brpk), offer promising treatment options. Although FMT is widely used to treat recurrent CDI, its use in gastrointestinal and metabolic diseases remains limited. Future research directions include optimizing donor selection, understanding microbial mechanisms, and exploring the potential of FMT for treating other diseases. Ongoing research not only aims to broaden its indications but also improves its safety and efficacy. Emerging therapies such as VE303 (Vedanta) are being studied to refine treatment approaches and expand the use of microbiota-based therapies. Further studies are needed to standardize guidelines, improve patient outcomes, and better define the role of FMT in the treatment of diseases beyond recurrent CDI.
|
KSGE
